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Cholinergic precursors have represented the first approach recognized from a 
regulatory point of view to counter cognitive impairment occurring in adult-onset 
dementia disorders. ASCOMALVA [Effect of association between a cholinesterase 
inhibitor (ChE-I) and choline alphoscerate on cognitive deficits in AD associated with 
cerebrovascular injury] is a double-blind, controlled, randomized clinical trial inves-
tigating if the ChE-I donepezil and the cholinergic precursor choline alphoscerate in 
combination are more effective that donepezil alone. In this study, MRI from ACO-
MALVA patients were analyzed for the evaluation of brain atrophy. 
Participants to the ASCOMALVA trial underwent yearly MRI for diagnostic pur-
poses. In 56 patients who achieved two years of therapy, MRI scans were analyzed by 
voxel morphometry techniques to assess if addition of choline alphoscerate to treat-
ment with donepezil had an effect on brain volume changes known to occur in AD. 
Reference group patients (treated with donepezil alone) developed a greater atro-
phy of the gray and white matter compared with the group treated with donepezil 
plus choline alphoscerate. In the reference group a concomitant increase of the space 
of the cerebrospinal fluid and of the volume of the ventriculi was noticeable. One 
of the most affected areas was the hippocampus. Neuropsycological tests over the 
24-month observation period showed in patients of the reference group a moderate 
time-dependent worsening in all the parameters investigated. Treatment with done-
pezil plus choline alphoscerate resulted in better scores of the cognitive and function-
al items and in an improvement in behavioural parameters, superior to that induced 
by donepezil alone. 
The above results have shown that treatment with choline alphoscerate plus 
donepezil versus donepezil alone counters to some extent hippocampal volume loss 
occurring in the brain of AD patients. The observation of a parallel improvement 
of cognitive and functional tests in patients treated with the cholinergic precursor 
loading strategy using choline alphoscerate indicates that morphological changes 
observed by MRI may have functional relevance. 
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